Topical formulation for a JAK inhibitor
AssigneeIncyte Corporation
InventorsBhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Life of this patent
Estimating the term…
Abstract
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Claims29
A method of treating a skin disorder in a human patient in need thereof, comprising:
- applying to the patient's skin a pharmaceutically acceptable composition comprising:
- an oil-in-water emulsion, comprising:
- water, an oil component, an emulsifier component, a solvent component, and from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt, wherein the oil-in-water emulsion in the composition is a solubilized cream and further wherein the oil-in-water emulsion has a pH of not greater than 3.6;
- wherein treating is one or more of inhibiting the skin disorder and ameliorating the skin disorder;
- and wherein the skin disorder is an autoimmune skin disorder.
A method of inhibiting JAK1 and/or JAK2 in a human patient suffering from a skin disorder, comprising:
- applying to the patient's skin a pharmaceutically acceptable composition comprising:
- an oil-in-water emulsion, comprising:
- water,
- an oil component,
- an emulsifier component,
- a solvent component, and
- from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt,
- wherein the oil-in-water emulsion in the composition is a solubilized cream and further wherein the oil-in-water emulsion has a pH of not greater than 3.6.
A method of treating atopic dermatitis in a human patient, comprising:
- applying to the patient's skin a pharmaceutically acceptable composition comprising:
- an oil-in-water emulsion, comprising:
- water,
- an oil component,
- an emulsifier component,
- a solvent component, and
- from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt,
- wherein the oil-in-water emulsion in the composition is a solubilized cream and further wherein the oil-in-water emulsion has a pH of not greater than 3.6;
- and
- wherein treating is one or more of inhibiting atopic dermatitis and ameliorating atopic dermatitis.
A method of treating atopic dermatitis in a human patient, comprising:
- applying to the patient's skin a pharmaceutically acceptable composition comprising:
- an oil-in-water emulsion, comprising:
- water,
- an oil component,
- an emulsifier component,
- a solvent component, and
- about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt,
- wherein the oil-in-water emulsion in the composition is a solubilized cream and further wherein the oil-in-water emulsion has a pH of not greater than 3.6;
- and
- wherein treating is one or more of inhibiting atopic dermatitis and ameliorating atopic dermatitis.
Dependencies are inferred from the claim text.